Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals.
-
Clinical Benefit
Substantial
The actual benefit of RANEXA in this indication is substantial.
Clinical Added Value
no clinical added value
RANEXA should be used only by patients with stable angina that is inadequately controlled or who are intolerant to betablockers and/or calcium channel blockers. Given the data available, RANEXA does not provide any improvement in actual benefit (IABV) in the management of these patients.
Listen
